Table 2.

Multivariate analysis with hazard model for nestin in the whole series and in ER+ subgroup

	Multivariate Analysis for BCSS in the whole series (n=3234)		Multivariate Analysis for BCSS in the ER+ subgroup (n=2323)
Variable	HR (95% CI)	P-value	HR (95% CI)	P-value
Nestin+ vs. Nestin−	1.24 (1.00–1.54)	0.05	1.39 (1.00–1.93)	0.05
Age ≥ 60 vs. < 60, years	1.13 (0.98–1.31)	0.09	1.12 (0.95–1.33)	0.18
Tumor size >2 vs. ≤2, cm	1.59 (1.37–1.84)	<0.001	1.60 (1.34–1.92)	<0.001
Grade {3} vs. {1,2}	1.50 (1.28–1.77)	<0.001	1.50 (1.26–1.81)	<0.001
Nodal status positive vs. negative	1.90 (1.61–2.23)	<0.001	1.88 (1.55–2.30)	<0.001
Lymphovascular Invasion positive vs. negative	1.39 (1.18–1.63)	<0.001	1.28 (1.05–1.56)	0.02
ER positive vs. negative	0.82 (0.70–0.97)	0.02	----	----
Her2 positive vs. negative	1.37 (1.14–1.64)	0.001	1.27 (0.97–1.65)	0.08
ki67 {≥14%} vs. {<14%}	1.42 (1.22–1.64)	<0.001	1.60 (1.33–1.9)	<0.001

BCSS: Breast cancer specific survival; ER: Estrogen receptor; Her2: Human epidermal growth factor receptor-2.